Lupin launches hypertension drug in US
The company's valsartan tablet is the AB rated generic equivalent of Novartis' Diovan tablet, which had annual US sales of $2.08 bn
Lupin Pharmaceuticals Ltd, Lupin's US subsidiary, has launched its valsartan tablets USP 40 mg, 80 mg, 160 mg and 320 mg, having received final approval from the US Food & Drug Administration (USFDA). Lupin's valsartan tablet, which is the AB rated generic equivalent of Novartis' Diovan tablet, is indicated for the treatment of hypertension and heart failure.
As per IMS MAT September 2014, Diovan tablets had annual US sales of $2.08 billion.
As per IMS MAT September 2014, Diovan tablets had annual US sales of $2.08 billion.